Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that specializes in developing innovative treatments for cancer and other debilitating diseases. Based in the United Kingdom, the company utilizes its proprietary bicyclic peptide technology to create highly targeted therapies that can selectively bind to specific disease targets while minimizing side effects. Bicycle Therapeutics’ lead product candidate, BT1718, is currently being evaluated in clinical trials for the treatment of solid tumors. The company has also established partnerships with leading pharmaceutical companies, including AstraZeneca and Bioverativ, to develop novel therapies using its bicyclic peptide platform. With a mission to transform the lives of patients through the power of its technology, Bicycle Therapeutics is committed to advancing groundbreaking treatments that have the potential to revolutionize healthcare.
